What Is End Systolic Volume and Why Does It Matter?

End-systolic volume (ESV) is the amount of blood left inside a heart chamber at the end of each contraction. A healthy left ventricle typically holds somewhere around 50 to 60 milliliters of blood at that moment, though the number varies by body size, sex, and fitness level. Clinicians care about ESV because it captures something that more familiar numbers like heart rate or blood pressure miss: how well the heart muscle is actually squeezing, and whether the chamber is stretching out over time in ways that signal trouble ahead.

What ESV Reveals About the Heart Muscle

Every heartbeat is a cycle of filling and emptying. Blood flows in during relaxation (diastole), and the chamber squeezes it out during contraction (systole). The volume at peak filling is end-diastolic volume (EDV), and the volume left behind after squeezing is ESV. The difference between the two is stroke volume, the amount of blood sent out with each beat. Ejection fraction, the percentage most people hear about, is simply stroke volume divided by EDV. So ESV is baked into every ejection-fraction calculation, but it carries its own independent information.

A rising ESV often means the heart muscle is weakening or the chamber is dilating, sometimes both. After a heart attack, for example, damaged muscle may stop contracting, which means more blood stays behind at the end of each beat. Over weeks and months, that extra residual blood stretches the chamber wall, which makes the next contraction even less efficient, which leaves even more blood behind. Cardiologists call that vicious cycle “adverse remodeling,” and tracking ESV is one of the clearest ways to catch it early.

How Contractility and ESV Are Linked

Researchers in the 1970s figured out that if you plot the pressure inside the ventricle against its volume at the end of systole across a range of conditions, you get a remarkably straight line. The steeper that line, the stronger the heart muscle is contracting. During a positive inotropic intervention, where something makes the muscle squeeze harder, the pressure-volume loop shifts to a smaller ESV and a higher end-systolic pressure, pushing the slope of the relationship upward and to the left.¹ This end-systolic pressure-volume relationship is considered a more reliable index of true contractility than other common measures like the peak rate of pressure rise inside the chamber.²

One subtlety: the slope of that relationship stays steady across a wide range of afterload conditions (the resistance the heart pumps against), but the volume intercept, where the line crosses the volume axis, does shift with changes in arterial resistance.³ In practical terms, this means ESV on its own is not a pure measure of contractility: blood pressure, valve function, and vascular stiffness all tug at the number. That is exactly why clinicians look at ESV alongside ejection fraction, blood pressure, and imaging of wall motion rather than treating any single metric as the whole story.

How ESV Is Measured

The most common way to estimate ESV in a clinic is echocardiography, essentially an ultrasound of the heart. A method called Simpson’s method of discs traces the inner border of the ventricle in two views and stacks the resulting slices mathematically to estimate total volume.⁴ It is fast, portable, and does not expose you to radiation. The trade-off is that image quality depends heavily on body habitus and operator skill, and measurements can vary from one sonographer to the next.

Cardiac MRI is widely regarded as the reference standard for ventricular volume quantification because it produces high-resolution, three-dimensional images of the heart that are less dependent on acoustic windows or operator technique.⁵ It is more expensive and time-consuming than echo, so it tends to be reserved for situations where precise volumes really matter, like planning surgery, monitoring certain cardiomyopathies, or settling a disagreement between echo and clinical findings.

A newer development is the use of deep-learning algorithms that can trace ventricular borders automatically during an echocardiogram. In one study, automated deep-learning measurements of ESV were substantially more reproducible than manual measurements, with the minimum detectable change dropping by about 44 percent for ESV.⁶ Machine-learning analysis of cardiac MRI images has also shown promise, generating time-volume curves in about two and a half minutes compared to roughly 43 minutes for manual analysis, with no significant differences in the size and function parameters extracted.⁷ These tools are not replacing the human reader yet, but they are making routine volume tracking faster and more consistent.

ESV After a Heart Attack

One of the strongest demonstrations of ESV’s clinical value comes from heart attack research. When a coronary artery is reopened and blood flow is restored, the left ventricular ESV measured just 90 to 180 minutes into reperfusion therapy turns out to be a powerful predictor of both short-term and long-term survival. Patients whose indexed ESV (ESV adjusted for body size) reached 40 mL/m² or higher at that very early time point had roughly 3.4 times the odds of dying within 30 days and about 4.1 times the odds of dying within a year.⁸

A higher threshold has been identified for patients with ischemic dilated cardiomyopathy, a condition where previous heart attacks have left the heart enlarged and weakened. In that population, an ESV index of 60 mL/m² or above has been linked to increased cardiac mortality, and this threshold has been used to guide decisions about surgical ventricular reconstruction, a procedure that removes scarred heart muscle to shrink the chamber.⁹

Tracking the direction of ESV change after a heart attack is just as telling as the absolute number. Researchers have categorized post-infarction patients into groups based on whether their volumes shrank, held steady, or grew. Those whose ESV decreased by 12 percent or more, labeled “reverse remodeling,” had the best long-term prognosis, while those whose both ESV and EDV increased by 12 percent or more, representing adverse remodeling, fared worst.¹⁰ The clinical takeaway: what the heart does with its ESV in the weeks after an infarction may matter more than the snapshot taken at admission.

Predicting Heart Failure Hospitalization

ESV’s prognostic power extends well beyond the acute heart attack setting. In the Heart and Soul Study, which followed patients with stable coronary artery disease, those in the highest quartile of ESV index (above 25 mL/m²) were hospitalized for heart failure about nine times as often as those in the lowest quartile (below 13 mL/m²). Even after adjusting for a long list of potential confounders, the association held: the highest-quartile group still had roughly five times the risk of heart failure hospitalization.¹¹ Interestingly, the same study found that while high ESV predicted death in unadjusted analyses, that association disappeared after accounting for other risk factors. ESV’s sweet spot as a predictor seems to be heart failure events specifically.

A separate study confirmed that even in patients whose ejection fraction is technically preserved, meaning it looks normal on paper, ESV index can flag future trouble. Those with an ESV index above about 24 mL/m² had significantly worse event-free survival, with ESV independently predicting new-onset heart failure alongside age and levels of brain natriuretic peptide, a well-known heart failure biomarker.¹² This matters because heart failure with preserved ejection fraction has long been difficult to predict and diagnose early. ESV provides a clue that the chamber geometry is drifting in a dangerous direction even when the ejection fraction still looks reassuring.

Why ESV Sometimes Tells You More Than Ejection Fraction

Ejection fraction is the cardiac metric most patients know, the one that appears on every echo report and drives most treatment guidelines. But ejection fraction has blind spots. It is a ratio, and ratios can be misleading when both the numerator and the denominator are moving. A heart that is dilating might maintain a deceptively normal-looking ejection fraction for a while because the EDV is growing alongside the ESV. The absolute ESV, meanwhile, is steadily climbing, and that climb correlates with worsening outcomes.

This discrepancy has been investigated in aortic regurgitation, a leaky aortic valve that forces the heart to handle extra volume with each beat. In asymptomatic patients with chronic aortic regurgitation, ESV index was independently associated with death under medical surveillance: for every 5 mL/m² increase, the hazard of dying rose by about 11 percent. Patients whose ESV index exceeded 45 mL/m² had roughly a 1.9-fold increased risk of death. End-diastolic volume index, by contrast, was not independently associated with mortality.¹³ Current guidelines for aortic regurgitation recommend considering surgery before the ejection fraction drops below 55 percent or the left ventricular end-systolic dimension reaches 55 mm, reflecting the importance of end-systolic size in surgical timing.¹⁴

Medications and Devices That Shrink ESV

Because a falling ESV signals reverse remodeling and better outcomes, many heart failure therapies are judged at least partly by whether they bring ESV down. ACE inhibitors like enalapril and captopril were among the first drugs shown to do this. In patients with left ventricular dysfunction after a heart attack, captopril reduced both EDV and ESV while improving ejection fraction and stroke volume, likely by lowering the load the heart pumps against and blunting the hormonal signals that drive chamber enlargement.¹⁵

A newer combination drug, sacubitril/valsartan, has shown even more striking effects. In patients who experienced reverse remodeling on this medication, ESV dropped from an average of about 139 mL to 94 mL, a substantial reduction. Stroke volume increased, and the coupling between the heart’s pumping ability and the arterial system it pumps into improved dramatically, with overall cardiac efficiency rising from about 46 to 57 percent.¹⁶

On the device side, cardiac resynchronization therapy (CRT), a specialized pacemaker that coordinates the timing of the heart’s electrical signals, has been shown to significantly reduce both end-systolic and end-diastolic dimensions.¹⁷ Response to CRT varies widely, though. A subgroup of “super-responders” who experience dramatic ESV reduction are more likely to be women, and research has clarified that a given drop in ESV does not translate into the same ejection fraction improvement in every patient, partly because the relationship between the two metrics depends on the starting chamber size.¹⁸

ESV in Athletes

If a large ESV generally signals a sick heart, what about endurance athletes, whose hearts are famously large? This is where context matters enormously. Trained athletes can have resting ESVs nearly double those of sedentary individuals. In one study, athletes had an average resting ESV of about 50 mL compared to roughly 29 mL in untrained subjects. During exercise, untrained subjects uniformly dropped their ESV as contractility ramped up, but about 41 percent of the athletes actually maintained or slightly increased their ESV during exercise.¹⁹

This does not indicate a weak heart. Athletes develop larger chambers and thicker walls as an adaptation to sustained high-output training. Their hearts fill with more blood per beat and eject more per beat, so even though the absolute ESV is higher, the system is working efficiently. The danger is that this physiological enlargement can look like early cardiomyopathy on a standard echo if the clinician is not aware the patient is an athlete. Distinguishing “athlete’s heart” from pathological dilation usually requires additional context: training history, the pattern of enlargement, diastolic function, and sometimes cardiac MRI or exercise testing.

The Right Ventricle

Most conversations about ESV focus on the left ventricle because it does the heavy lifting of systemic circulation, but the right ventricle matters too, especially in pulmonary hypertension. The right ventricle pumps blood through the lungs, and when pulmonary artery pressure rises, the right ventricle has to work harder. Over time it can dilate and fail, and its end-systolic properties become clinically relevant.

Researchers have used pressure-volume analysis on the right side to assess coupling between the right ventricle and the pulmonary arteries in patients with pulmonary arterial hypertension. Right ventricular end-systolic elastance, the stiffness of the right ventricle at end-systole, and its diastolic counterpart both carry prognostic weight. Baseline right ventricular diastolic stiffness above a certain threshold was associated with worse long-term survival even in patients already receiving treatment.²⁰ Right ventricular assessment remains harder than left ventricular assessment because the right ventricle has an irregular crescent shape that resists the geometric assumptions built into standard echo formulas. Cardiac MRI is increasingly used when right-sided volumes need to be accurate.

Measuring ESV in Children

Pediatric cardiology faces its own challenges with ESV. Children’s hearts are growing, so “normal” volumes change with age and body size. Generating reliable reference ranges is complicated by the fact that younger, smaller children are more likely to have technically difficult echocardiograms. In the Pediatric Heart Network’s database of normal echocardiograms, about 17 percent of children had at least one functional parameter fall below commonly used cutoffs for normal, and the children flagged as abnormal tended to be younger and smaller.²¹ Whether those results reflect true variation in normal hearts or measurement artifacts in small, fast-beating chests is an ongoing debate.

Cardiac MRI reference values for children are similarly sparse. The analysis methods used to trace ventricular borders on MRI have not been standardized across pediatric centers, and the normal values that do exist are based on relatively small samples.²² For children with congenital heart disease, where serial volume measurements guide decisions about surgeries that may happen years apart, this inconsistency is a real problem. A volume that looks reassuring measured one way might cross a worrisome threshold measured another way, and the child’s cardiologist needs to know which method was used and how it compares.